GenomeDx Announces Cigna Coverage for Decipher Prostate Cancer Tests

GenomeDx Announces Cigna Coverage for Decipher Prostate Cancer Tests

June 21, 2018 — Decipher obtains positive coverage decisions for both the biopsy and post-surgical prostate settings — SAN DIEGO, June 21, 2018 /PRNewswire/ — GenomeDx Biosciences, a leader in the field of urologic cancer genomics, announced today that Cigna® issued positive medical

Johnson & Johnson Innovation Opens JLABS @ NYC in Collaboration with New York State and the New York Genome Center

Johnson & Johnson Innovation Opens JLABS @ NYC in Collaboration with New York State and the New York Genome Center

June 21, 2018 Life Science Incubator Selects New QuickFire Challenge Winners to Join JLABS @ NYC NEW YORK, June 21, 2018 /PRNewswire/ — Johnson & Johnson Innovation LLC today announced the opening of JLABS @ NYC. The 30,000-square foot facility, located at the New

Oramed Initiates Food Effect Study for Its Oral Insulin Capsule ORMD-0801

Oramed Initiates Food Effect Study for Its Oral Insulin Capsule ORMD-0801

June 21, 2018 NEW YORK, June 21, 2018 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has initiated a food effect study in the U.S. for its

Trovagene Announces the Start of Recruitment and Enrollment for Phase 2 Clinical Trial of PCM-075 in Combination with Zytiga® in Patients with mCRPC

Trovagene Announces the Start of Recruitment and Enrollment for Phase 2 Clinical Trial of PCM-075 in Combination with Zytiga® in Patients with mCRPC

June 21, 2018 Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute and Massachusetts General Hospital officially activated and recruiting patients for Phase 2 open-label trial of PCM-075 and abiraterone acetate (Zytiga®) in metastatic Castration-Resistant Prostate Cancer (mCRPC) SAN DIEGO, June 21,

Hygieia Signs Commercial Agreement Making d-Nav® Insulin Guidance Service Available to At-Risk Blue Cross Blue Shield of Michigan Members in Southeast Michigan

Hygieia Signs Commercial Agreement Making d-Nav® Insulin Guidance Service Available to At-Risk Blue Cross Blue Shield of Michigan Members in Southeast Michigan

June 21, 2018 — First U.S. commercial contract demonstrates potential for Service to improve standard of care for large Type 2 diabetes population — LIVONIA, Mich., June 21, 2018 /PRNewswire/ — Hygieia, a digital insulin enhancement company dedicated to making insulin therapy easier

Caris Life Sciences Presents Data Demonstrating the Ability of ADAPT Biotargeting System to Identify Responders and Non-Responders in a Phase III Pancreatic Cancer Study

Caris Life Sciences Presents Data Demonstrating the Ability of ADAPT Biotargeting System to Identify Responders and Non-Responders in a Phase III Pancreatic Cancer Study

June 21, 2018 Leveraging ADAPT Biotargeting System would have significantly increased the probability of success Data presented at the ESMO World Congress on Gastrointestinal Cancer 2018 IRVING, Texas, June 21, 2018 /PRNewswire/ — Caris Life Sciences®, a leading innovator in molecular science focused on

Nature Study Leverages Artificial Intelligence to Reveal Never-before-seen Cage Structure of Ultra-small Particles

Nature Study Leverages Artificial Intelligence to Reveal Never-before-seen Cage Structure of Ultra-small Particles

June 20, 2018 These New Findings Support Benefits of Elucida’s C-Dot Technology and Pave the Way for Applications in Medicine, Catalysis, Energy, Optics and Other Areas NEW YORK, June 20, 2018 /PRNewswire/ — Elucida Oncology, a biotechnology company developing a first-in-class nanotechnology platform,

Stratus Pharmaceuticals Announces Results Of FDA Inspection To Stratus’s Distribution Center

Stratus Pharmaceuticals Announces Results Of FDA Inspection To Stratus’s Distribution Center

June 20, 2018 MIAMI, June 20, 2018 /PRNewswire/ — Stratus Pharmaceuticals has received correspondence from the FDA indicating the Establishment Inspection Report (EIR) results of the inspection that took place during 03/06/2018 to 03/08/2018 , showing that there were no 483 Items and as

Aminex Therapeutics Initiates First Clinical Trial of Novel Immunotherapy AMXT 1501 + DFMO in Cancer Patients

Aminex Therapeutics Initiates First Clinical Trial of Novel Immunotherapy AMXT 1501 + DFMO in Cancer Patients

June 20, 2018 Polyamine depletion therapy represents a unique cancer immunotherapy approach SEATTLE, June 20, 2018 /PRNewswire/ — Aminex Therapeutics, Inc., a clinical-stage drug development company focused on advancing a novel cancer immunotherapy, today announced it received clearance from the Food and Drug Administration

Steba Biotech’s TOOKAD® Vascular Photodynamic Therapy Maintains Significant Reduction in Overall Progression and Conversion to Radical Therapy in Low-risk Prostate Cancer Patients at 4 Years

Steba Biotech’s TOOKAD® Vascular Photodynamic Therapy Maintains Significant Reduction in Overall Progression and Conversion to Radical Therapy in Low-risk Prostate Cancer Patients at 4 Years

June 20, 2018 LUXEMBOURG, June 20, 2018 /PRNewswire/ — Steba Biotech, a privately-owned biotechnology company focused on the development of innovative and minimally invasive photodynamic therapies and systems to treat cancers, today announced that the Journal of Urology has published 4-year follow

Targovax Granted EU Patent for Mutant-RAS Neoantigen Platform 2nd Generation Product TG02

Targovax Granted EU Patent for Mutant-RAS Neoantigen Platform 2nd Generation Product TG02

June 19, 2018 Provides IP protection of TG02 in Europe until 09.12.2033 OSLO, Norway, June 19, 2018 /PRNewswire/ — Targovax ASA (“Targovax” or “the Company”; OSE: TRVX), is a clinical stage company focused on developing and commercializing immune activators to target hard to

University of Missouri School of Medicine, Roche collaborate on first US implementation of tumor board software that improves treatment decision process for cancer patients

University of Missouri School of Medicine, Roche collaborate on first US implementation of tumor board software that improves treatment decision process for cancer patients

June 19, 2018 MU pilots Roche’s cloud-based NAVIFY Tumor Board solution to streamline and standardize data collection and presentation, enabling faster, better collaboration among oncology care teams INDIANAPOLIS and COLUMBIA, Mo., June 19, 2018 /PRNewswire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the

Amgen Receives European Commission Approval To Add Overall Survival Data To BLINCYTO® (blinatumomab) Label

Amgen Receives European Commission Approval To Add Overall Survival Data To BLINCYTO® (blinatumomab) Label

June 19, 2018 BLINCYTO is the First-and-Only Approved Bispecific CD19-Directed CD3 T Cell Engager (BiTE®) Immunotherapy THOUSAND OAKS, Calif., June 19, 2018 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced that the European Commission (EC) has granted a full marketing authorization for BLINCYTO® (blinatumomab) based

GenomeDx Biosciences and Pathnostics Launch Enhanced Version of Guidance Tests

GenomeDx Biosciences and Pathnostics Launch Enhanced Version of Guidance Tests

June 19, 2018 — Now Offering Both Phenotype and Genotype Testing for Antibiotic Resistance — SAN DIEGO and Irvine, Calif., June 19, 2018 /PRNewswire/ — GenomeDx Biosciences and Pathnostics today announced the launch of the next generation Guidance testing for patients suffering from simple

Kazia Releases Preliminary Cantrixil Phase I Data

Kazia Releases Preliminary Cantrixil Phase I Data

SYDNEY, June 19, 2018 /PRNewswire/ — Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to provide an interim update to shareholders regarding its phase I clinical trial of Cantrixil (TRX-E-002-1) in relapsed or recurrent ovarian cancer. The phase

Robotics: Changing the Face of Drug Discovery – PharmaBoardroom

Robotics: Changing the Face of Drug Discovery – PharmaBoardroom

June 19, 2018 While the automotive and electronics industries, among others, have been relatively fast in adopting robotics, pharma has been lagging behind. However, as the technology available becomes more advanced, flexible and affordable, robotics now stands as a pivotal

DreaMed Diabetes Granted FDA Authorization to Market Advisor Pro, Offering Personalized Optimization of Insulin Pump Therapy

DreaMed Diabetes Granted FDA Authorization to Market Advisor Pro, Offering Personalized Optimization of Insulin Pump Therapy

June 18, 2018 Agreement with Glooko Provides Broad Access of Insulin Pump Therapy Optimization to Physicians, Patients and Payers PETAH TIKVA, Israel, June 18, 2018 /PRNewswire/ — DreaMed Diabetes, developer of personalized diabetes management solutions, announced today that the U.S Food and Drug Administration

Array BioPharma to Present Overall Survival Results from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant Colorectal Cancer at the ESMO 20th World Congress on Gastrointestinal Cancer

Array BioPharma to Present Overall Survival Results from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant Colorectal Cancer at the ESMO 20th World Congress on Gastrointestinal Cancer

June 18, 2018 – Encore investor webcast presentation June 23, 2018 – BOULDER, Colo., June 18, 2018 /PRNewswire/ — Array BioPharma Inc. (Nasdaq: ARRY) announced that it will present updated safety and efficacy results, including overall survival (OS) data, from the safety lead-in

Published Case Report Demonstrates the Clinical Utility of Biocept’s CTC Platform in the Management of Patients with Metastatic Breast Cancer

Published Case Report Demonstrates the Clinical Utility of Biocept’s CTC Platform in the Management of Patients with Metastatic Breast Cancer

June 18, 2018 Peer-reviewed article in journal Clinics in Oncology highlights ability of Biocept’s Target Selector™ to detect a key biomarker to qualify breast cancer patients for targeted therapy when tissue biopsy is inconclusive SAN DIEGO, June 18, 2018 /PRNewswire/ — Biocept, Inc. (NASDAQ: BIOC),

Champions Oncology Partners with Puma Biotechnology and NSABP Foundation on Metastatic Breast and Colon Cancer Co-clinical PDX Studies

Champions Oncology Partners with Puma Biotechnology and NSABP Foundation on Metastatic Breast and Colon Cancer Co-clinical PDX Studies

June 18, 2018 HACKENSACK, N.J., June 18, 2018 /PRNewswire/ — Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that they have partnered with NSABP Foundation,

Migraine Abortion Phase 3 Trial (TEAM study) with Cefaly® ACUTE Medical Device is Progressing Quickly

Migraine Abortion Phase 3 Trial (TEAM study) with Cefaly® ACUTE Medical Device is Progressing Quickly

June 18, 2018 The Cefaly® ACUTE medical device, recently cleared by the U.S. Food and Drug Administration (FDA) for the acute treatment of migraine, is the subject of a large phase 3 clinical trial in the United States that is progressing rapidly. Previous pilot

Elekta Unity, World’s First High-Field MR-Linac, Receives CE Mark

Elekta Unity, World’s First High-Field MR-Linac, Receives CE Mark

une 18, 2018 New radiation therapy system will now be implemented clinically in Europe, ushering in a transformation in precisionand personalized cancer treatment Elekta (EKTA-B.ST) earlier today announced (14:15 CET) that its Elekta Unity magnetic resonance radiation therapy (MR/RT) system has received CE mark, clearing the technology for

The US FDA Approves First Supplemental Abbreviated New Drug Application (sANDA) for Glenmark Pharmaceuticals’ Manufacturing Facility in Monroe, North Carolina

The US FDA Approves First Supplemental Abbreviated New Drug Application (sANDA) for Glenmark Pharmaceuticals’ Manufacturing Facility in Monroe, North Carolina

June 18, 2018 sANDA approval is for manufacturing of Atovaquone and Proguanil Hydrochloride Tablets, 250 MG/100 MG AND 62.5 MG/25 MG at Monroe facility PARAMUS, N.J., June 18, 2018 /PRNewswire/ — Glenmark Pharmaceuticals, a global pharmaceutical company, today announced that the U.S.

Hyundai Hope On Wheels Presents Phoenix Children’s Hospital With $100,000 Hyundai Impact Award To Support Pediatric Cancer Research

Hyundai Hope On Wheels Presents Phoenix Children’s Hospital With $100,000 Hyundai Impact Award To Support Pediatric Cancer Research

June 18, 2018 The organization will surpass $145 million in lifetime funding celebrating its 20th Year in ‘Saving Lives and Creating Hope’ to End Childhood Cancer PHOENIX, June 18, 2018 /PRNewswire/ — Hyundai Hope On Wheels® 501(c)(3) non-profit organization, celebrates its 20th year in

Mylan Launches Generic Angiomax® Injection

Mylan Launches Generic Angiomax® Injection

June 18, 2018 – Bivalirudin for Injection is an anticoagulant intended for use with aspirin – HERTFORDSHIRE, England and PITTSBURGH, June 18, 2018 /PRNewswire/ — Global pharmaceutical company Mylan N.V.(NASDAQ: MYL) today announced the U.S. launch of Bivalirudin for Injection, 250 mg single-dose vial, a generic